Annals of Hematology

, Volume 96, Issue 11, pp 1833–1840 | Cite as

The impact of antimicrobial prophylaxis in morbidity and infections during azacitidine treatment

  • Natalia Lorenzana
  • Laura Francisca Avila
  • Sara Alonso
  • Enrique Colado
  • Teresa Bernal
Original Article

Abstract

The clinical consequences of the infectious events in patients receiving azacitidine are poorly documented. Likewise, the role of primary antimicrobial prophylaxis is unknown. In this retrospective, single-center study, we compare the impact of prophylaxis on the incidence of infection and morbidity in all consecutive higher-risk myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) patients, during the first 4 azacitidine cycles. Seventy-six patients, corresponding to 283 azacitidine cycles, were studied. There were infectious events in 43% of the patients. Development of infections led to more hospital admissions, increased red blood cells and platelet requirements, and a delay in subsequent cycles. Median overall survival was comparable between patients with or without infections. In the multivariate analysis, a neutrophil count below 0.5 × 109/L (OR 12.5 [2.6–50]) and antimicrobial prophylaxis (OR 0.1 [0.02–04]) were independent factors for the development of infection. We conclude that infectious events have a significant impact in the early clinical course of azacitidine-treated patients by increasing hospital admissions and transfusion requirements. Antimicrobial prophylaxis may prevent infections, leading to a decreased need for supportive care in these patients with poor outcome.

Keywords

Myelodysplastic syndrome Acute myeloid leukemia Azacitidine Antimicrobial prophylaxis Febrile neutropenia 

Notes

Acknowledgements

Instituto Universitario de Oncología del Principado de Asturias is supported by Fundación Bancaria Caja de Ahorros de Asturias.

Compliance with ethical standards

Conflicts of interest

The authors declare that they have no conflicts of interest.

References

  1. 1.
    Dombret H, Seymour JF, Butrym A, Wierzbowska A, Selleslag D, Jang JH, Kumar R, Cavenagh J, Schuh AC, Candoni A, Recher C, Sandhu I, Bernal del Castillo T, Al-Ali HK, Martinelli G, Falantes J, Noppeney R, Stone RM, Minden MD, McIntyre H, Songer S, Lucy LM, Beach CL, Dohner H (2015) International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood 126:291–299CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Damaj G, Duhamel A, Robin M, Beguin Y, Michallet M, Mohty M, Vigouroux S, Bories P, Garnier A, El Cheikh J, Bulabois CE, Huynh A, Bay JO, Legrand F, Deconinck E, Fegueux N, Clement L, Dauriac C, Maillard N, Cornillon J, Ades L, Guillerm G, Schmidt-Tanguy A, Marjanovic Z, Park S, Rubio MT, Marolleau JP, Garnier F, Fenaux I, Yakoub-Agha I (2012) Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Societe Francaise de Greffe de Moelle et de Therapie-Cellulaire and the Groupe-francophone des Myelodysplasies. J Clin Oncol 30:4533–4540CrossRefPubMedGoogle Scholar
  3. 3.
    Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, Schoch R, Gattermann N, Sanz G, List A, Gore SD, Seymour JF, Bennett JM, Byrd J, Backstrom J, Zimmerman L, McKenzie D, Beach C, Silverman LR, International Vidaza High-Risk MDSSSG (2009) Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 10:223–232CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Seymour JF, Dohner H, Minden MD, Stone R, Gambini D, Dougherty D, Beach CL, Weaver J, Dombret H (2017) Incidence rates of treatment-emergent adverse events and related hospitalization are reduced with azacitidine compared with conventional care regimens in older patients with acute myeloid leukemia. Leuk Lymphoma 58:1412–1423CrossRefPubMedGoogle Scholar
  5. 5.
    Gafter-Gvili A, Fraser A, Paul M, Leibovici L (2005) Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 142:979–995CrossRefPubMedGoogle Scholar
  6. 6.
    Fenaux P, Bowen D, Gattermann N, Hellstrom-Lindberg E, Hofmann WK, Pfeilstocker M, Sanz G, Santini V (2010) Practical use of azacitidine in higher-risk myelodysplastic syndromes: an expert panel opinion. Leuk Res 34:1410–1416CrossRefPubMedGoogle Scholar
  7. 7.
    Merkel D, Filanovsky K, Gafter-Gvili A, Vidal L, Aviv A, Gatt ME, Silbershatz I, Herishanu Y, Arad A, Tadmor T, Dally N, Nemets A, Rouvio O, Ronson A, Herzog-Tzarfati K, Akria L, Braester A, Hellmann I, Yeganeh S, Nagler A, Leiba R, Mittelman M, Ofran Y (2013) Predicting infections in high-risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine: a retrospective multicenter study. Am J Hematol 88:130–134CrossRefPubMedGoogle Scholar
  8. 8.
    Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079–2088PubMedGoogle Scholar
  9. 9.
    Cordoba I, Gonzalez-Porras JR, Such E, Nomdedeu B, Luno E, de Paz R, Carbonell F, Vallespi T, Ardanaz M, Ramos F, Marco V, Bonanad S, Sanchez-Barba M, Costa D, Bernal T, Sanz GF, Canizo MC (2012) The degree of neutropenia has a prognostic impact in low risk myelodysplastic syndrome. Leuk Res 36:287–292CrossRefPubMedGoogle Scholar
  10. 10.
    Gonzalez-Porras JR, Cordoba I, Such E, Nomdedeu B, Vallespi T, Carbonell F, Luno E, Ardanaz M, Ramos F, Pedro C, Gomez V, de Paz R, Sanchez-Barba M, Sanz GF, Del Canizo AC, Spanish Myelodysplastic Syndrome R (2011) Prognostic impact of severe thrombocytopenia in low-risk myelodysplastic syndrome. Cancer 117:5529–5537CrossRefPubMedGoogle Scholar
  11. 11.
    Sorror ML, Giralt S, Sandmaier BM, De Lima M, Shahjahan M, Maloney DG, Deeg HJ, Appelbaum FR, Storer B, Storb R (2007) Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. Blood 110:4606–4613CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Maertens J, Marchetti O, Herbrecht R, Cornely OA, Fluckiger U, Frere P, Gachot B, Heinz WJ, Lass-Florl C, Ribaud P, Thiebaut A, Cordonnier C, Third European Conference on Infections in L (2011) European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3--2009 update. Bone Marrow Transplant 46:709–718CrossRefPubMedGoogle Scholar
  13. 13.
    Schuck A, Goette MC, Neukirchen J, Kuendgen A, Gattermann N, Schroeder T, Kobbe G, Germing U, Haas R (2017) A retrospective study evaluating the impact of infectious complications during azacitidine treatment. Ann Hematol 96(7):1097–1104CrossRefPubMedGoogle Scholar
  14. 14.
    Giles FJ, Borthakur G, Ravandi F, Faderl S, Verstovsek S, Thomas D, Wierda W, Ferrajoli A, Kornblau S, Pierce S, Albitar M, Cortes J, Kantarjian H (2007) The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. Br J Haematol 136:624–627CrossRefPubMedGoogle Scholar
  15. 15.
    Malfuson JV, Etienne A, Turlure P, de Revel T, Thomas X, Contentin N, Terre C, Rigaudeau S, Bordessoule D, Vey N, Gardin C, Dombret H, Acute Leukemia French A (2008) Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia. Haematologica 93:1806–1813CrossRefPubMedGoogle Scholar
  16. 16.
    Schellongowski P, Staudinger T, Kundi M, Laczika K, Locker GJ, Bojic A, Robak O, Fuhrmann V, Jager U, Valent P, Sperr WR (2011) Prognostic factors for intensive care unit admission, intensive care outcome, and post-intensive care survival in patients with de novo acute myeloid leukemia: a single center experience. Haematologica 96:231–237CrossRefPubMedGoogle Scholar
  17. 17.
    Molina R, Bernal T, Borges M, Zaragoza R, Bonastre J, Granada RM, Rodriguez-Borregan JC, Nunez K, Seijas I, Ayestaran I, Albaiceta GM, Investigators Es (2012) Ventilatory support in critically ill hematology patients with respiratory failure. Crit Care 16:R133CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Itzykson R, Thepot S, Quesnel B, Dreyfus F, Beyne-Rauzy O, Turlure P, Vey N, Recher C, Dartigeas C, Legros L, Delaunay J, Salanoubat C, Visanica S, Stamatoullas A, Isnard F, Marfaing-Koka A, de Botton S, Chelghoum Y, Taksin AL, Plantier I, Ame S, Boehrer S, Gardin C, Beach CL, Ades L, Fenaux P, Groupe Francophone des M (2011) Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood 117:403–411CrossRefPubMedGoogle Scholar
  19. 19.
    Falantes JF, Calderon C, Marquez-Malaver FJ, Aguilar-Guisado M, Martin-Pena A, Martino ML, Montero I, Gonzalez J, Parody R, Perez-Simon JA, Espigado I (2014) Patterns of infection in patients with myelodysplastic syndromes and acute myeloid leukemia receiving azacitidine as salvage therapy. Implications for primary antifungal prophylaxis. Clin Lymphoma Myeloma Leuk 14:80–86CrossRefPubMedGoogle Scholar
  20. 20.
    Bow EJ (2009) Neutropenic fever syndromes in patients undergoing cytotoxic therapy for acute leukemia and myelodysplastic syndromes. Semin Hematol 46:259–268CrossRefPubMedGoogle Scholar
  21. 21.
    Sekeres MA, Stone RM, Zahrieh D, Neuberg D, Morrison V, De Angelo DJ, Galinsky I, Lee SJ (2004) Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome. Leukemia 18:809–816CrossRefPubMedGoogle Scholar
  22. 22.
    Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH (2006) Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106:2258–2266CrossRefPubMedGoogle Scholar
  23. 23.
    Santini V, Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Silverman LR, List A, Gore SD, Seymour JF, Backstrom J, Beach CL (2010) Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*. Eur J Haematol 85:130–138PubMedPubMedCentralGoogle Scholar
  24. 24.
    Diamantopoulos P, Zervakis K, Papadopoulou V, Iliakis T, Kalala F, Giannakopoulou N, Rougala N, Galanopoulos A, Bakarakos P, Variami E, Dimitrakopoulou A, Viniou NA (2015) 5-Azacytidine in the treatment of intermediate-2 and high-risk myelodysplastic syndromes and acute myeloid leukemia. A five-year experience with 44 consecutive patients. Anticancer Res 35:5141–5147PubMedGoogle Scholar
  25. 25.
    Bernal T, Martinez-Camblor P, Sanchez-Garcia J, de Paz R, Luno E, Nomdedeu B, Ardanaz MT, Pedro C, Amigo ML, Xicoy B, del Canizo C, Tormo M, Bargay J, Valcarcel D, Brunet S, Benlloch L, Sanz G, Spanish Group on Myelodysplastic S, Foundation P, Spanish Society of H (2015) Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry. Leukemia 29:1875–1881CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany 2017

Authors and Affiliations

  1. 1.Servicio de Hematología y HemoterapiaHospital Universitario Central de AsturiasOviedoSpain
  2. 2.Departamento de MedicinaInstituto Universitario de Oncología del Principado de Asturias, Universidad de OviedoOviedoSpain

Personalised recommendations